Endocannabinoid pathways, as part of the endocannabinoid system (ECS), play a critical role in regulating appetite, energy balance, and metabolic homeostasis. The ECS is composed of the signalling molecules anandamide and 2-AG as well as the CB1 and CB2 receptors, that modulate appetite and fat storage. Endocannabinoid signalling dysregulation may lead to obesity, insulin resistance, and other metabolic dysregulation, frequently resulting in upregulated appetite and fat accumulation. Pharmacological modulation of the endocannabinoid pathways may offer therapeutic targets aimed at obesity and improving metabolic health. Endocannabinoid pathway research has also stemmed into understanding their relationship with hormone concentrations, gut microbiota, and lipid metabolism. This broader understanding highlights how ECS modulation can improve metabolic outcomes related to obesity and its complications.
Connect, collaborate, and contribute to driving excellence in obesity research, clinical practice, and public health approaches globally.
